Abstract
Efficacy and safety analysis from PATRICIA’s cohorts A & B showed that palbociclib plus trastuzumab is safe, exhibiting promising survival outcomes in trastuzumab pretreated HER2+/HR+ PAM50 Luminal A/B advanced BC (Ciruelos E. et al, CCR 2020), that were maintained after a median of >3 years of follow-up. Based on these encouraging results, PATRICIA trial is currently randomizing patients with HER2+/HR+, PAM50 Luminal tumors to palbociclib, trastuzumab and ET or TPC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have